Literature DB >> 21988366

Identification of expanded alleles of the FMR1 gene among high-risk population in Indonesia by using blood spot screening.

Tri Indah Winarni1, Agustini Utari, Farmaditya E P Mundhofir, Tzuhan Tong, Blythe Durbin-Johnson, Sultana M H Faradz, Flora Tassone.   

Abstract

The prevalence of Fragile X Syndrome (FXS) is 1 in 4000 in males and 1 in 2500 in males and females, respectively, in the general population. Several screening studies aimed at determining the prevalence of FXS have been conducted in individuals with intellectual disabilities (IDs) with a prevalence varying from 1.15% to 6.3% across different ethnic groups. A previous study in Indonesia showed an FXS prevalence of 1.9% among the ID population. A rapid, effective, and inexpensive method for FMR1 screening, using dried blood spots capable of detecting an expanded FMR1 allele in both males and females, was recently reported. We used this approach to screen 176 blood spots, collected from Central Java, Indonesia, for the presence of expanded FMR1 gene alleles. Samples were collected from high-risk populations: 112 individuals with ID, 32 obtained from individuals with diagnosis of autism spectrum disorders, and 32 individuals with a known family history of FXS. Fourteen subjects carrying an FMR1 expanded allele were identified including 7 premutations (55-200 CGG repeats) and 7 full mutations (>200 repeats). Of the seven subjects identified with a full mutation, one subject was from a non-fragile X family, and six from were families with a history of FXS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21988366      PMCID: PMC3306584          DOI: 10.1089/gtmb.2011.0089

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  57 in total

1.  Molecular screening for fragile X syndrome among Indonesian children with developmental disability.

Authors:  S M Faradz; M Buckley; D Leigh; J J Holden
Journal:  Am J Med Genet       Date:  1999-04-02

2.  The fragile X prevalence paradox.

Authors:  Paul J Hagerman
Journal:  J Med Genet       Date:  2008-04-15       Impact factor: 6.318

3.  Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation.

Authors:  Faraz Farzin; Hazel Perry; David Hessl; Danuta Loesch; Jonathan Cohen; Susan Bacalman; Louise Gane; Flora Tassone; Paul Hagerman; Randi Hagerman
Journal:  J Dev Behav Pediatr       Date:  2006-04       Impact factor: 2.225

4.  Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation.

Authors:  David Hessl; Flora Tassone; Danuta Z Loesch; Elizabeth Berry-Kravis; Maureen A Leehey; Louise W Gane; Ingrid Barbato; Cathlin Rice; Emma Gould; Deborah A Hall; James Grigsby; Jacob A Wegelin; Susan Harris; Foster Lewin; Dahlia Weinberg; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-11-05       Impact factor: 3.568

5.  FMRP expression as a potential prognostic indicator in fragile X syndrome.

Authors:  F Tassone; R J Hagerman; D N Iklé; P N Dyer; M Lampe; R Willemsen; B A Oostra; A K Taylor
Journal:  Am J Med Genet       Date:  1999-05-28

6.  Association of FMR1 repeat size with ovarian dysfunction.

Authors:  A K Sullivan; M Marcus; M P Epstein; E G Allen; A E Anido; J J Paquin; M Yadav-Shah; S L Sherman
Journal:  Hum Reprod       Date:  2004-12-17       Impact factor: 6.918

7.  Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors.

Authors:  Walter E Kaufmann; Ranon Cortell; Alice S M Kau; Irena Bukelis; Elaine Tierney; Robert M Gray; Christiane Cox; George T Capone; Pia Stanard
Journal:  Am J Med Genet A       Date:  2004-09-01       Impact factor: 2.802

8.  Expanded clinical phenotype of women with the FMR1 premutation.

Authors:  Sarah M Coffey; Kylee Cook; Nicole Tartaglia; Flora Tassone; Danh V Nguyen; Ruiqin Pan; Hannah E Bronsky; Jennifer Yuhas; Mariya Borodyanskaya; Jim Grigsby; Melanie Doerflinger; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2008-04-15       Impact factor: 2.802

Review 9.  Prevalence of FMR1 repeat expansions in movement disorders. A systematic review.

Authors:  D A Hall; R J Hagerman; P J Hagerman; S Jacquemont; M A Leehey
Journal:  Neuroepidemiology       Date:  2006-02-21       Impact factor: 3.282

Review 10.  Lessons from fragile X regarding neurobiology, autism, and neurodegeneration.

Authors:  Randi J Hagerman
Journal:  J Dev Behav Pediatr       Date:  2006-02       Impact factor: 2.225

View more
  5 in total

1.  Most Martin-Bell syndrome (FMR1-related disorder) Venezuelan patients did not show CGG expansion but instead display genetic heterogeneity.

Authors:  Yasser Vega; Sergio Arias; Irene Paradisi
Journal:  J Hum Genet       Date:  2016-10-06       Impact factor: 3.172

2.  Distribution of AGG interruption patterns within nine world populations.

Authors:  Carolyn M Yrigollen; Stefan Sweha; Blythe Durbin-Johnson; Lili Zhou; Elizabeth Berry-Kravis; Isabel Fernandez-Carvajal; Sultana Mh Faradz; Khaled Amiri; Huda Shaheen; Roberta Polli; Luis Murillo-Bonilla; Gabriel de Jesus Silva Arevalo; Patricia Cogram; Alessandra Murgia; Flora Tassone
Journal:  Intractable Rare Dis Res       Date:  2014-11

3.  Cascade Screening for Fragile X Syndrome/CGG Repeat Expansions in Children Attending Special Education in Sri Lanka.

Authors:  C H W M R Bhagya Chandrasekara; W S Sulochana Wijesundera; Hemamali N Perera; Samuel S Chong; Indhu-Shree Rajan-Babu
Journal:  PLoS One       Date:  2015-12-22       Impact factor: 3.240

4.  A Single Common Assay for Robust and Rapid Fragile X Mental Retardation Syndrome Screening From Dried Blood Spots.

Authors:  Vivienne J Tan; Mulias Lian; Sultana M H Faradz; Tri I Winarni; Samuel S Chong
Journal:  Front Genet       Date:  2018-11-27       Impact factor: 4.599

5.  Screening for FMR1 CGG Repeat Expansion in Thai Patients with Autism Spectrum Disorder.

Authors:  Areerat Hnoonual; Charunee Jankittunpaiboon; Pornprot Limprasert
Journal:  Biomed Res Int       Date:  2021-12-08       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.